Status:
COMPLETED
Effect of Genetic Polymorphism on Calcineurin Inhibitors Levels in Egyptian Renal Transplant Patients
Lead Sponsor:
Helwan University
Collaborating Sponsors:
Ain Shams University
Conditions:
Renal Transplantation
Eligibility:
All Genders
18-80 years
Brief Summary
Renal transplantation is the treatment of choice for patients with end-stage renal disease (ESRD). Calcineurin Inhibitors tacrolimus and cyclosporine are the principle immunosuppressive agents adminis...
Detailed Description
Tacrolimus and cyclosporine are the principle immunosuppressive agents administered to solid organ transplant recipients to prevent and treat allograft rejection.They both exert their immunosppressive...
Eligibility Criteria
Inclusion
- Kidney transplant patients.
- Treatment with calcineurin inhibitors (CNI) either Cyclosporine (Neoral®) or Tacrolimus (Prograf®).
- Absence of medication known to interact with CNI
- Age18 years and more
Exclusion
- Patient who experience acute rejection, graft failure.
- Medications that interact with Calcineurin Inhibitors.
- Pregnant or nursing women.
- Patients who decline to participate
Key Trial Info
Start Date :
March 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 29 2020
Estimated Enrollment :
143 Patients enrolled
Trial Details
Trial ID
NCT03830255
Start Date
March 1 2017
End Date
March 29 2020
Last Update
March 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain shams university specialized hospital
Cairo, Egypt